P01537998A02
The_DD fifth_JJ strategy_NN involved_VVD a_DD combination_NN of_II accelerated_VVNJ rt-PA_NN and_CC intravenous_JJ urokinase_NN (_( regimen_NN E_NN )_) ._.
P01555101A04
Successful_JJ lysis_NN was_VBD achieved_VVN in_II 40_MC of_II 98_MC patients_NNS (_( 41_MC per_II cent_MC )_) receiving_VVG streptokinase_NN and_CC 40_MC of_II 69_MC patients_NNS (_( 58_MC per_II cent_MC )_) receiving_VVG rtPA_NN (_( P_NN less_RR than_CSN 0.05_MC )_) ._.
P01729881A03
Recombinant_JJ tissue_NN plasminogen_NN activator_NN (_( rt-PA_NN )_) is_VBZ more_RR potent_JJ for_II coronary_JJ arterial_JJ thrombolysis_NN ,_, producing_VVG both_CC more_RR rapid_JJ and_CC more_RR frequent_JJ recanalization_NN (_( approximately_RR 75_MC %_SYM patency_NN at_II 90_MC minutes_NNS )_) with_II a_DD dose_NN of_II 100_MC mg_NN given_VVN over_II 3_MC hours_NNS ._.
P01828324A07
Thrombolysis_NN was_VBD successful_JJ in_II 30_MC and_CC unsuccessful_JJ in_II 11_MC patients_NNS ._.
P01899546A08
Fourth_RR ,_, lysis_NN at_II 90_MC minutes_NNS is_VBZ of_II minimal_JJ relevance_NN for_II myocardial_JJ salvage_NN unless_CS observed_VVN within_II the_DD time_NN frame_NN when_PNR infarction_NN size_NN can_VM be_VBB limited_VVN significantly_RR ,_, which_PNR is_VBZ generally_RR less_RR than_CSN 4_MC hours_NNS between_II symptom_NN onset_NN and_CC the_DD time_NN that_CST reperfusion_NN is_VBZ accomplished_VVN ._.
P01900225A09
CONCLUSION_NN ._.
P01900313A04
In_II the_DD rt-PA_NN group_NN ,_, this_DD activity_NN decreased_VVD significantly_RR (_( p_NN less_RR than_CSN 0.001_MC )_) after_II the_DD infusion_NN and_CC remained_VVD depressed_VVN throughout_II the_DD 1st_JJ 4_MC days_NNS ._.
P01902439A06
A_DD second_JJ group_NN was_VBD evaluated_VVN for_II reocclusion_NN up_II+ to_II one_MC month_NN ._.
P01903167A02
All_DD patients_NNS entered_VVD the_DD trial_NN within_II 6_MC h_NN of_II the_DD onset_NN of_II symptoms_NNS and_CC underwent_VVD baseline_NN coronary_JJ angiography_NN of_II the_DD infarct-related_VVNJ coronary_JJ artery_NN before_CS thrombolytic_JJ therapy_NN was_VBD instituted_VVN ._.
P01903404A07
In_II group_NN B_NN ,_, 10_MC day_NN patency_NN of_II the_DD infarct-related_VVNJ artery_NN was_VBD 67_MC %_SYM ;_: there_EX was_VBD no_DD difference_NN in_II patency_NN by_II treatment_NN assignment_NN or_CC in_II left_JJ ventricular_JJ function_NN or_CC infarct_NN size_NN between_II patients_NNS with_II and_CC without_II infarct-related_VVNJ artery_NN patency_NN ._.
P01904028A02
Electrocardiograms_NNS (_( ECG_NN )_) obtained_VVN at_II admission_NN ,_, 6_MC h_NN and_CC 10_MC to_II 22_MC days_NNS after_II the_DD start_NN of_II therapy_NN were_VBD analysed_VVN ._.
P01904629A06
The_DD results_NNS of_II this_DD study_NN show_VVB that_CST even_RR a_DD dosage_NN of_II lower_JJR than_CSN 0.5_MC mg_NN /_SYM kg_NN /_SYM 24_MC hr_NN might_VM prove_VVB to_TO be_VBI effective_JJ ._.
P01905875A02
Patients_NNS were_VBD treated_VVN 2.1_MC +/-_SYM 0.8_MC hours_NNS after_II the_DD onset_NN of_II symptoms_NNS ._.
P01909760A01
A_DD comparison_NN was_VBD made_VVN between_II several_JJ characteristics_NNS of_II tissue-type_NN plasminogen_NN activator_NN (_( t-PA_NN )_) and_CC urokinase_NN (_( UK_NN )_) ,_, potentially_RR useful_JJ in_II microsurgery_NN to_TO restore_VVI perfusion_NN to_II ischemic_JJ free-tissue_NN transfers_NNS ._.
P01913123A05
The_DD median_JJ (_( confidence_NN interval_NN )_) increase_NN in_II ankle_NN :_: brachial_JJ pressure_NN index_NN following_VVG IA_NN rt-PA_NN of_II 0.57_MC (_( 0.33-0.82_MC )_) was_VBD significantly_RR higher_JJR than_CSN for_II either_CC Sk_NN of_II 0.24_MC (_( 0-0.57_MC )_) or_CC for_II IV_NN rt-PA_NN of_II 0.18_MC (_( 0-0.41_MC )_) ._.
P01974704A06
In_II two_MC patients_NNS the_DD thrombolytic_JJ treatment_NN was_VBD successful_JJ (_( the_DD patients_NNS improved_VVD clinically_RR )_) ;_: the_DD third_JJ patient_NN died_VVD of_II massive_JJ cerebral_JJ infarct-related_VVNJ oedema_NN ._.
P02105682A11
These_DD results_NNS indicate_VVB ,_, at_RR+ least_RR in_II the_DD model_NN employed_VVN ,_, that_CST compared_VVN with_II treatment_NN with_II UK_NN ,_, pulmonary_JJ thrombolysis_NN and_CC corresponding_VVGJ hemodynamic_JJ improvement_NN are_VBB greatest_JJT with_II rtPA_NN ._.
P02106403A01
The_DD effects_NNS of_II simultaneous_JJ intravenous_JJ infusions_NNS of_II 12_MC mg_NN recombinant_JJ tissue-type_NN plasminogen_NN activator_NN (_( rt-PA_NN )_) over_II 30_MC minutes_NNS and_CC 48_MC mg_NN single-chain_NN urokinase-type_NN plasminogen_NN activator_NN (_( scuPA_NN )_) over_II 40_MC minutes_NNS were_VBD studied_VVN in_II 38_MC patients_NNS with_II acute_JJ myocardial_JJ infarction_NN ._.
P02107957A08
In_II two_MC patients_NNS following_VVG t-PA_NN alone_JJ ,_, rethrombosis_NN occurred_VVD after_II 2_MC and_CC 11_MC days_NNS ._.
P02108851A09
Other_JJ factors_NNS such_II+ as_II patient_NN age_NN ,_, the_DD likelihood_NN of_II the_DD diagnosis_NN of_II MI_NN ,_, and_CC the_DD estimated_VVNJ risk_NN of_II bleeding_VVGN should_VM also_RR be_VBB considered_VVN ._.
P02110271A03
Nineteen_MC patients_NNS were_VBD excluded_VVN as_CS they_PN did_VDD not_RR meet_VVB the_DD inclusion_NN criteria_NNS ._.
P02119673A05
The_DD different_JJ dosage_NN regimens_NNS of_II rt-PA_NN recently_RR evaluated_VVN (_( 0.71_MC to_II 1.76_MC mg_NN /_SYM kg_NN /_SYM 24_MC h_NN for_II 2-4_MC days_NNS )_) in_II DVT_NN have_VHB caused_VVN consistent_JJ thrombolysis_NN but_CC also_RR excessive_JJ bleeding_VVGN ._.
P02120309A01
When_CS conventional_JJ treatment_NN of_II patients_NNS with_II early_JJ clinical_JJ reinfarction_NN after_II thrombolytic_JJ therapy_NN fails_VVZ ,_, mechanical_JJ revascularization_NN may_VM be_VBB attempted_VVN ._.
P02121073A03
The_DD test_NN revealed_VVD activation_NN of_II platelets_NNS and_CC coagulation_NN by_II SK_NN and_CC rt-PA_NN ._.
P02129372A12
Therefore_RR ,_, thrombolytic_JJ therapy_NN will_VM probably_RR become_VVB routine_JJ therapy_NN for_II early_JJ acute_JJ myocardial_JJ infarction_NN ._.
P02495318A03
In_II the_DD absence_NN of_II stenosis_NN ,_, intravenous_JJ infusion_NN of_II 750,000_MC U_NN of_II streptokinase_NN over_II 1_MC h_NN caused_VVD reperfusion_NN in_II five_MC of_II six_MC dogs_NNS in_II 34_MC +/-_SYM 25_MC min_NN (_( mean_NN +/-_SYM SD_NN )_) ._.
P02501898A03
Successful_JJ lysis_NN was_VBD seen_VVN in_II 18_MC (_( 86_MC %_SYM )_) patients_NNS following_VVG r-tPA_NN and_CC in_II 15_MC (_( 65_MC %_SYM )_) patients_NNS following_VVG streptokinase_NN ._.
P02508227A03
The_DD development_NN of_II persistent_JJ antibodies_NNS or_CC direct_JJ induction_NN of_II hypotension_NN has_VHZ not_RR been_VBN reported_VVN ,_, nor_CC has_VHZ significant_JJ activation_NN of_II the_DD complement_NN system_NN ._.
P02512687A03
"_`` In_JJ+ vitro_JJ "_'' clot_NN lysis_NN assays_NNS with_II fibrinogen-I125_NN were_VBD also_RR evaluated_VVN with_II the_DD same_JJ agents_NNS at_II 1_MC ,_, 3_MC and_CC 7_MC days_NNS ._.
P02953761A05
Patients_NNS treated_VVN with_II SK_NN showed_VVD extensive_JJ further_JJ plasmin_NN degradation_NN of_II fragment_NN X_NN to_II fragments_NNS Y_NN and_CC D_NN ._.
P03109764A07
The_DD occurrence_NN of_II bleeding_VVGJ events_NNS ,_, administration_NN of_II blood_NN transfusions_NNS ,_, and_CC reocclusion_NN of_II the_DD infarct-related_VVNJ artery_NN was_VBD comparable_JJ in_II the_DD two_MC groups_NNS ._.
P03115077A01
The_DD effect_NN of_II combined_VVNJ intravenous_JJ infusion_NN of_II 10_MC mg_NN of_II recombinant_JJ tissue-type_NN plasminogen_NN activator_NN (_( rt-PA_NN )_) and_CC 10_MC mg_NN of_II recombinant_JJ single-chain_NN urokinase-type_NN plasminogen_NN activator_NN over_II 1_MC hour_NN on_II coronary_JJ artery_NN recanalization_NN and_CC on_II the_DD blood_NN fibrinolytic_JJ system_NN was_VBD studied_VVN in_II 9_MC patients_NNS with_II acute_JJ myocardial_JJ infarction_NN and_CC angiographically_RR confirmed_VVN coronary_JJ artery_NN occlusion_NN ._.
P03117859A02
Although_CS originally_RR isolated_VVN from_II urine_NN ,_, pro-urokinase_NN is_VBZ also_RR found_VVN in_II blood_NN ,_, where_PNR it_PN is_VBZ believed_VVN to_TO participate_VVI in_II natural_JJ fibrinolysis_NN alongside_II tissue_NN plasminogen_NN activator_NN (_( t-PA_NN )_) ._.
P07474300A02
The_DD frequency_NN of_II PVC_NN and_CC the_DD mortality_NN rate_NN were_VBD evaluated_VVN in_II anesthetized_VVNJ dogs_NNS which_PNR had_VHD 1-_MC ,_, 3-_MC or_CC 6-h-old_JJ thrombi_NNS induced_VVN by_II a_DD copper_NN coil_NN in_II the_DD coronary_JJ artery_NN ._.
P07494361A01
PURPOSE_NN :_: Presumed_VVNJ differences_NNS in_II the_DD thrombolytic_JJ activity_NN and_CC fibrinolytic_JJ specificity_NN of_II the_DD three_MC commonly_RR used_VVNJ thrombolytic_JJ agents_NNS ,_, streptokinase_NN ,_, urokinase_NN ,_, and_CC recombinant_JJ tissue_NN plasminogen_NN activator_NN (_( rt-PA_NN )_) ,_, are_VBB based_VVN on_II clinical_JJ study_NN results_NNS ,_, where_PNR variability_NN renders_VVZ meaningful_JJ comparisons_NNS difficult_JJ ._.
P07563451A03
SETTING_VVGN --_: A_DD total_NN of_II 75_MC hospitals_NNS in_II 14_MC European_NN countries_NNS ._.
P07563451A17
There_EX were_VBD no_DD statistically_RR significant_JJ differences_NNS in_II the_DD mortality_NN rate_NN at_II 30_MC days_NNS or_CC in_II the_DD overall_JJ incidence_NN of_II intracerebral_JJ hemorrhages_NNS among_II the_DD rt-PA_NN and_CC placebo_NN treatment_NN arms_NNS in_II either_DD analysis_NN ._.
P07594099A10
The_DD median_JJ hospital_NN stay_NN was_VBD 7_MC days_NNS ,_, 2_MC fewer_JJR than_CSN the_DD overall_JJ stay_NN in_II GUSTO-I_NN ._.
P07608437A09
All_DD patients_NNS received_VVD intravenous_JJ heparin_NN and_CC oral_JJ aspirin_NN ._.
P07723799A06
Our_PNG primary_JJ ,_, or_CC base-case_NN ,_, analysis_NN of_II cost_NN effectiveness_NN used_VVD data_NNS from_II the_DD GUSTO_NN study_NN and_CC life_NN expectancy_NN projected_VVN on_II the_DD basis_NN of_II the_DD records_NNS of_II survivors_NNS of_II myocardial_JJ infarction_NN in_II the_DD Duke_NN Cardiovascular_JJ Disease_NN Database_NN ._.
P07745771A01
OBJECTIVE_NN --_: To_TO examine_VVI differences_NNS in_II outcomes_NNS and_CC patient_NN management_NN between_II patients_NNS in_II the_DD United_VVNJ States_NNS and_CC outside_II the_DD United_VVNJ States_NNS undergoing_VVG thrombolysis_NN for_II acute_JJ myocardial_JJ infarction_NN ._.
P07851482A09
It_PN is_VBZ concluded_VVN that_CST thromboxane_NN A2_NN ,_, thrombin_NN and_CC leucocytes_NNS are_VBB involved_VVN in_II reocclusion_NN after_II thrombolysis_NN ._.
P07878629A05
Radiographic_JJ contrast_NN injection_NN showed_VVD 7_MC catheters_NNS randomized_VVN to_II UK_NN had_VHD complete_JJ resolution_NN of_II the_DD thrombus_NN compared_VVN to_II 17_MC randomized_VVN to_II t-PA_NN (_( p_NN =_SYM 0.042_MC )_) ._.
P07963104A01
OBJECTIVES_NNS ._.
P07994806A12
CONCLUSIONS_NNS :_: Our_PNG results_NNS show_VVB that_CST both_DD thrombolytic_JJ agents_NNS activate_VVB the_DD classic_JJ complement_NN pathway_NN and_CC that_CST plasmin_NN could_VM be_VBB the_DD common_JJ trigger_NN for_II this_DD phenomenon_NN ._.
P08092895A05
Additional_JJ endpoints_NNS were_VBD reduction_NN in_II surgical_JJ procedure_NN ,_, clinical_JJ outcome_NN classification_NN ,_, length_NN of_II hospitalization_NN ,_, and_CC outcome_NN by_II duration_NN of_II ischemia_NN ._.
P08092895A19
Patients_NNS with_II acute_JJ ischemia_NN (_( 0-14_MC days_NNS )_) who_PNR were_VBD treated_VVN with_II thrombolysis_NN had_VHD improved_VVNJ amputation-free_JJ survival_NN and_CC shorter_JJR hospital_NN stays_NNS ._.
P08213579A01
A_DD blinded_VVNJ ,_, randomized_VVNJ trial_NN compared_VVD the_DD effects_NNS of_II front-loaded_VVNJ streptokinase_NN with_II those_PND of_II the_DD conventional_JJ dose_NN of_II intravenous_JJ recombinant_JJ tissue-type_NN plasminogen_NN activator_NN (_( rt-PA_NN )_) on_II left_JJ ventricular_JJ (_( LV_NN )_) function_NN after_II acute_JJ myocardial_JJ infarction_NN (_( AMI_NN )_) ._.
P08250455A02
DESIGN_NN :_: Uncontrolled_VVNJ randomized_VVNJ study_NN ._.
P08281367A09
Four_MC patients_NNS underwent_VVD successful_JJ ,_, semiurgent_JJ percutaneous_JJ transluminal_JJ coronary_JJ angioplasty_NN ;_: three_MC received_VVD an_DD elective_JJ and_CC two_MC an_DD urgent_JJ coronary_JJ artery_NN bypass_NN graft_NN ._.
P08328203A04
Thirty_MC ,_, 60_MC ,_, 90_MC ,_, and_CC 120_MC min_NN after_II initiation_NN of_II rt-PA_NN infusion_NN ,_, specific_JJ t-PA_NN activities_NNS in_II plasma_NN of_II responders_NNS were_VBD 0.62_MC ,_, 0.63_MC ,_, 0.62_MC ,_, and_CC 0.57_MC (_( IU_NN /_SYM ng_NN /_SYM ml_NN )_) ,_, respectively_RR ,_, as_CS compared_VVN to_II 0.42_MC ,_, 0.42_MC ,_, 0.40_MC ,_, and_CC 0.32_MC (_( IU_NN /_SYM ng_NN /_SYM ml_NN )_) in_II nonresponders_NNS (_( p_NN <_SYM 0.001_MC )_) ._.
P08354802A11
Bleeding_VVGN and_CC hemorrhagic_JJ and_CC ischemic_JJ stroke_NN rates_NNS were_VBD similar_JJ among_II diabetic_JJ and_CC nondiabetic_JJ patients_NNS ._.
P08370015A01
Catheter-directed_VVNJ thrombolytic_JJ therapy_NN has_VHZ become_VVB an_DD important_JJ part_NN of_II the_DD treatment_NN of_II patients_NNS with_II acute_JJ arterial_JJ and_CC graft_NN occlusion_NN ._.
P08470843A01
STUDY_NN OBJECTIVE_NN :_: To_TO assess_VVI the_DD choice_NN of_II thrombolytic_JJ agents_NNS in_II emergency_NN departments_NNS and_CC whether_CST administrators_NNS and_CC third-party_NN payers_NNS are_VBB influencing_VVGJ choices_NNS because_II+ of_II cost_NN differences_NNS ._.
P08544674A01
PURPOSE_NN ._.
P08544674A16
When_CS the_DD chances_NNS of_II MI_NN and_CC death_NN are_VBB known_VVN ,_, decision_NN analysis_NN can_VM be_VBB a_DD useful_JJ bedside_NN tool_NN to_TO guide_VVI thrombolytic_JJ therapy_NN and_CC subsequently_RR ,_, if_CS needed_VVN ,_, to_TO review_VVI and_CC defend_VVI the_DD treatment_NN decisions_NNS made_VVN ._.
P08554022A09
A_DD transient_JJ decrease_NN occurred_VVD in_II the_DD type_NN I_MC propeptide_NN concentration_NN at_II postinfarction_NN day_NN 2_MC ,_, and_CC this_DD decrease_NN was_VBD followed_VVN by_II a_DD secondary_JJ increase_NN at_II days_NNS 4_MC to_II 6_MC in_II both_DD patient_NN groups_NNS studied_VVN ._.
P08598594A01
OBJECTIVE_NN :_: To_TO compare_VVI baseline_NN characteristics_NNS ,_, complications_NNS ,_, and_CC treatment-specific_JJ outcomes_NNS of_II women_NNS and_CC men_NNS with_II acute_JJ myocardial_JJ infarction_NN treated_VVN with_II thrombolytic_JJ therapy_NN ._.
P08632624A05
Accelerated_VVNJ idioventricular_JJ rhythms_NNS (_( p_NN <_SYM 0.05_MC )_) occurred_VVD sooner_RRR following_VVG rtPA_NN than_CSN UK_NN treatment_NN ._.
P08696906A01
OBJECTIVE_NN :_: To_TO study_VVI the_DD efficacy_NN and_CC risks_NNS of_II local_JJ thrombolytic_JJ therapy_NN of_II peripheral_JJ arterial_JJ occlusions_NNS using_VVG rt-PA_NN ._.
P08732377A06
The_DD activity_NN of_II alpha-hydroxybutyrate_NN dehydrogenase_NN (_( HBDH_NN )_) in_II plasma_NN was_VBD centrally_RR analysed_VVN and_CC infarct_NN size_NN was_VBD defined_VVN as_II cumulative_JJ HBDH_NN release_NN per_II litre_NN of_II plasma_NN within_II 72_MC h_NN of_II the_DD first_JJ symptoms_NNS (_( Q_NN (_( 72_MC )_) )_) ._.
P08737217A09
Conversely_RR ,_, in_II patients_NNS undergoing_VVG thrombolysis_NN the_DD incidence_NN of_II left_JJ ventricular_JJ thrombosis_NN was_VBD lower_JJR when_CS the_DD left_JJ anterior_JJ descending_VVGJ coronary_JJ artery_NN was_VBD patent_JJ ,_, and_CC especially_RR when_CS an_DD early_JJ creatine_NN kinase_NN peak_NN ,_, suggestive_JJ of_II reperfusion_NN ,_, was_VBD recorded_VVN (_( 7_MC %_SYM )_) ._.
P08770844A04
Also_RR discussed_VVN are_VBB new_JJ thrombolytic_JJ agents_NNS and_CC the_DD effects_NNS of_II concomitant_JJ use_NN of_II other_JJ drugs_NNS as_II part_NN of_II the_DD treatment_NN regimen_NN ._.
P08793432A06
Large_JJ local_JJ haematomas_NNS occurred_VVD in_II 8_MC %_SYM of_II cases_NNS in_II the_DD urokinase_NN group_NN and_CC 15_MC %_SYM in_II the_DD rt-PA_NN group_NN ._.
P08795509A01
PURPOSE_NN :_: The_DD purpose_NN of_II this_DD study_NN was_VBD to_TO prospectively_RR evaluate_VVI the_DD treatment_NN of_II patients_NNS with_II occluded_VVNJ lower_JJR extremity_NN bypass_NN grafts_NNS ,_, comparing_VVG surgical_JJ revascularization_NN with_II catheter-directed_VVNJ thrombolysis_NN ._.
P08905435A03
rt-PA_NN therapy_NN was_VBD administered_VVN over_II a_DD 10-day_NN period_NN ._.
P08950493A02
It_PN has_VHZ also_RR been_VBN used_VVN to_TO treat_VVI thrombotic_JJ closure_NN complicating_VVG angioplasty_NN ,_, to_TO treat_VVI nonocclusive_JJ thrombosis_NN observed_VVN during_II angioplasty_NN ,_, and_CC to_TO pretreat_VVI patients_NNS with_II nonacute_JJ total_JJ occlusions_NNS before_II angioplasty_NN ._.
P08990404A04
An_DD accelerated_VVNJ dosage_NN regimen_NN was_VBD later_RR devised_VVN to_TO allow_VVI the_DD administration_NN of_II t-PA_NN over_II a_DD shorter_JJR period_NN of_II time_NN ._.
P08990407A02
As_II a_DD result_NN ,_, it_PN is_VBZ no_RR longer_RR ethical_JJ to_TO test_VVI a_DD new_JJ thrombolytic_JJ regimen_NN against_II placebo_NN ._.
P09052962A10
Two_MC major_JJ categories_NNS of_II patients_NNS were_VBD not_RR treated_VVN with_II thrombolysis_NN :_: 1_MC )_) patients_NNS presented_VVN more_RR than_CSN 12_MC hours_NNS after_II pain_NN onset_NN (_( 38_MC %_SYM )_) ;_: 2_MC )_) patients_NNS without_II ST_NN segment_NN elevation_NN or_CC LBBB_NN on_II the_DD ECG_NN presented_VVN (_( 37_MC %_SYM )_) ._.
P09061735A04
One_MC patient_NN presented_VVD mild_JJ respiratory_JJ distress_NN probably_RR from_II a_DD pulmonary_JJ microembolism_NN that_PNR disappeared_VVD in_II a_DD few_JJ days_NNS ._.
P09091523A05
In-hospital_NN clinical_JJ events_NNS and_CC mortality_NN at_II 30_MC days_NNS and_CC 1_MC year_NN were_VBD assessed_VVN ._.
P09127024A02
METHODS_NNS :_: Nine_MC patients_NNS were_VBD treated_VVN during_II a_DD 2-year_NN period_NN for_II intracranial_JJ dural_JJ sinus_NN thrombosis_NN ._.
P09134650A07
The_DD observation_NN that_CST neutralization_NN of_II PAI-1_NN by_II specific_JJ antibodies_NNS ,_, both_CC in_II plasma_NN and_CC within_II the_DD clot_NN ,_, did_VDD not_RR potentiate_VVB clot_NN lysis_NN indicates_VVZ that_CST the_DD inhibitor_NN ,_, including_VVG the_DD platelet-derived_VVNJ form_NN ,_, is_VBZ insufficient_JJ to_TO attenuate_VVI the_DD thrombolytic_JJ activity_NN of_II a_DD pharmacological_JJ concentration_NN of_II rt-PA_NN and_CC that_CST its_PNG elevation_NN ,_, similarly_RR to_II the_DD elevation_NN of_II plasminogen_NN ,_, is_VBZ not_RR the_DD cause_NN of_II clot_NN resistance_NN but_CC rather_RR a_DD coincident_JJ finding_VVGN ._.
P09134838A08
Eight_MC of_II ten_MC patients_NNS in_II the_DD thrombolysis_NN group_NN and_CC seven_MC of_II eight_MC with_II PTA_NN had_VHD clinical_JJ improvement_NN after_II the_DD procedure_NN ._.
P09173270A05
RESULTS_NNS :_: The_DD incidence_NN of_II the_DD primary_JJ end_NN point_NN in_II the_DD angioplasty_NN and_CC t-PA_NN groups_NNS was_VBD 9.6_MC percent_NN and_CC 13.7_MC percent_NN ,_, respectively_RR (_( odds_NNS ratio_NN ,_, 0.67_MC ;_: 95_MC percent_NN confidence_NN interval_NN ,_, 0.47_MC to_II 0.97_MC ;_: P_NN =_SYM 0.033_MC )_) ._.
P09207639A07
Mortality_NN was_VBD lowest_JJT among_II those_PND with_II diabetes_NN receiving_VVG accelerated_VVNJ t-PA_NN ,_, which_PNR is_VBZ consistent_JJ with_II the_DD results_NNS of_II the_DD overall_JJ patient_NN cohort_NN ._.
P09232304A13
CONCLUSION_NN :_: This_DD case_NN provides_VVZ evidence_NN for_II the_DD efficacy_NN and_CC relative_JJ safety_NN of_II rtPA_NN as_II thrombolytic_JJ therapy_NN in_II the_DD treatment_NN of_II haemodynamically_RR compromised_VVNJ valve_NN heart_NN thrombosis_NN in_II pregnancy_NN ._.
P09243149A07
CONCLUSION_NN :_: These_DD results_NNS proved_VVD that_CST ,_, when_CS the_DD full_JJ dose_NN of_II streptokinase_NN has_VHZ been_VBN given_VVN over_II 12_MC h_NN ,_, its_PNG efficacy_NN is_VBZ as_RR good_JJ as_CSN that_PND of_II 2_MC h_NN of_II recombinant_JJ tissue_NN plasminogen_NN ._.
P09284041A10
These_DD treatments_NNS may_VM reverse_VVB some_DD or_CC all_DD acute_JJ stroke_NN symptoms_NNS and_CC improve_VVB functional_JJ outcomes_NNS ._.
P09288042A04
METHODS_NNS :_: From_II all_DD available_JJ completed_VVNJ randomised_VVNJ trials_NNS of_II thrombolytic_JJ therapy_NN compared_VVN with_II control_NN in_II acute_JJ ischaemic_JJ stroke_NN (_( with_II prerandomisation_NN CT_NN )_) ,_, we_PN checked_VVD tabular_JJ data_NNS on_II deaths_NNS during_II roughly_RR the_DD first_JJ 2_MC weeks_NNS ,_, deaths_NNS from_II all_DD causes_NNS and_CC functional_JJ outcome_NN (_( disability_NN )_) at_II the_DD end_NN of_II the_DD trial_NN follow-up_NN period_NN ,_, and_CC early_JJ symptomatic_JJ and_CC fatal_JJ intracranial_JJ haemorrhages_NNS ._.
P09454430A04
The_DD results_NNS show_VVB that_CST thrombolysis_NN of_II acute_JJ carotid_JJ territory_NN strokes_NNS (_( European_NN Cooperative_NN Acute_JJ Stroke_NN Study_NN )_) and_CC of_II strokes_NNS with_II a_DD deficit_NN measurable_JJ on_II the_DD NIH_NN Stroke_NN Scale_NN (_( National_JJ Institute_NN of_II Neurological_JJ Disorders_NNS and_CC Stroke_NN rt-PA_NN Stroke_NN Study_NN )_) improves_VVZ clinical_JJ and_CC economic_JJ outcome_NN parameters_NNS in_II patients_NNS who_PNR were_VBD treated_VVN within_II 6_MC hours_NNS of_II the_DD onset_NN of_II symptoms_NNS and_CC had_VHD that_CST no_DD signs_NNS of_II extended_VVNJ early_JJ infarction_NN on_II the_DD initial_JJ CT-scan_NN ._.
P09491947A09
Some_DD patients_NNS were_VBD predicted_VVN to_TO benefit_VVI considerably_RR from_II thrombolysis_NN with_II little_DD extra_JJ risk_NN of_II stroke_NN and_CC vice_RR+ versa_RR :_: all_DD cases_NNS must_VM ,_, therefore_RR ,_, be_VBB assessed_VVN individually_RR ._.
P09525545A06
RESULTS_NNS :_: There_EX was_VBD no_DD difference_NN in_II baseline_NN clinical_JJ or_CC angiographic_JJ characteristics_NNS according_II+ to_II the_DD timing_VVGN or_CC nature_NN of_II treatment_NN ._.
P09576210A03
The_DD thrombolytic_JJ therapy_NN protocol_NN consisted_VVN of_II streptokinase_NN (_( 1,500,000_MC IU_NN in_II 90_MC minutes_NNS )_) (_( n_NN =_SYM 18_MC )_) in_II one_MC (_( n_NN =_SYM 7_MC )_) or_CC two_MC (_( n_NN =_SYM 11_MC )_) cycles_NNS or_CC recombinant_JJ tissue-type_NN plasminogen_NN activator_NN (_( 100_MC mg_NN in_II 90_MC minutes_NNS )_) (_( n_NN =_SYM 4_MC )_) ._.
P09626825A04
METHODS_NNS :_: Patients_NNS with_II symptoms_NNS of_II acute_JJ myocardial_JJ infarction_NN and_CC electrocardiographic_JJ ST_NN segment_NN elevation_NN were_VBD treated_VVN with_II thrombolytic_JJ therapy_NN and_CC randomly_RR assigned_VVN to_TO receive_VVI hirudin_NN or_CC heparin_NN ._.
P09631890A02
The_DD coronary_JJ endothelium_NN was_VBD removed_VVN and_CC thrombus_NN formation_NN was_VBD confirmed_VVN by_II angioscopy_NN ._.
P09878934A02
Therefore_RR there_EX might_VM be_VBB a_DD difference_NN in_II the_DD effect_NN of_II time_NN to_II treatment_NN on_II the_DD efficacy_NN of_II these_DD fibrinolytics_NNS with_II different_JJ fibrin_NN specificity_NN in_II patients_NNS with_II acute_JJ myocardial_JJ infarction_NN ._.
P10365238A10
Postthrombolisis_NN arrhythmias_NNS was_VBD observed_VVN in_II 64.7_MC %_SYM ._.
P10469440A09
In_II such_DD situations_NNS ,_, injection_NN of_II rt-PA_NN in_II the_DD pulp_NN soft_JJ tissues_NNS may_VM result_VVB in_II successful_JJ salvage_NN ._.
P10506849A07
Plasma_NN levels_NNS of_II lipid_NN peroxides_NNS (_( LPO_NN )_) were_VBD found_VVN to_TO increase_VVI 90_MC minutes_NNS after_II thrombolytic_JJ therapy_NN in_II each_DD group_NN ,_, while_CS the_DD levels_NNS of_II vitamins_NNS E_NN and_CC C_NN showed_VVD significant_JJ decreases_NNS ._.
P10545680A04
The_DD model_NN included_VVD three_MC outcome_NN states_NNS :_: death_NN ,_, nonfatal_JJ yet_RR disabling_VVGJ stroke_NN ,_, and_CC survival_NN with_II no_DD disabling_VVGJ stroke_NN ._.
P10572811A09
There_EX is_VBZ an_DD increased_VVNJ incidence_NN of_II stroke_NN with_II t-PA_NN ._.
P10695499A11
Controlled_VVNJ prospective_JJ multicentre_NN studies_NNS on_II thrombolytic_JJ therapy_NN in_II neonates_NNS and_CC infants_NNS are_VBB recommended_VVN to_TO evaluate_VVI patency_NN rates_NNS and_CC adverse_JJ effects_NNS for_II the_DD different_JJ thrombolytic_JJ agents_NNS used_VVN ._.
P10716384A09
These_DD risks_NNS appear_VVB similar_JJ to_II those_PND of_II urokinase_NN ._.
P10850102A06
Nevertheless_RR ,_, she_PN recovered_VVD well_RR from_II her_PNG hemiplegia_NN after_II a_DD few_JJ days_NNS ._.
P10865025A03
Thrombolysis_NN offers_VVZ a_DD promising_VVGJ alternative_NN to_II surgery_NN ._.
P11041123A07
After_II 24_MC hours_NNS the_DD t-PA_NN and_CC DD_NN plasma_NN levels_NNS remained_VVD significantly_RR higher_JJR (_( p_NN <_SYM 0.001_MC )_) while_CS the_DD PAI-1_NN plasma_NN levels_NNS returned_VVD to_II the_DD pre-therapy_NN levels_NNS ._.
P11315578A04
The_DD initial_JJ rt-PA_NN dose_NN was_VBD 0.4_MC mg_NN /_SYM kg_NN given_VVN over_II 15_MC min_NN and_CC followed_VVN by_II a_DD continuous_JJ daily_JJ infusion_NN of_II 1.6_MC to_II 2.0_MC mg_NN /_SYM kg_NN ._.
P11907772A05
RESULTS_NNS :_: Successful_JJ lysis_NN was_VBD achieved_VVN in_II all_DD patients_NNS ._.